USPTO serial 79445697
GLOMTHERA
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- MANCA, ALBERTO I
- Law office
- TMEG LAW OFFICE 108
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with GLOMTHERA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, medical and veterinary preparations and substances for the prevention, diagnosis and treatment of kidney diseases; reagents for use in medical genetic testing; biological, chemical and biochemical reagents for medical use; gene therapy products for medical and veterinary use; medical and veterinary preparations containing therapeutic DNA and RNA; biological, chemical, and biochemical reagents for medical purposes; pharmaceutical preparations, biological preparations, and gene therapy products for medical or pharmaceutical purposes, including, gene therapies, viral vectors, and nucleic-acid delivery products for use in the treatment of kidney diseases and disorders; pharmaceutical preparations for use in gene therapy; viral vectors for use in the delivery of gene therapy; adeno-associated virus (AAV) gene therapy; drug delivery agents consisting of capsids that facilitate delivery of pharmaceuticals and biopharmaceuticals; vaccines. | ACTIVE | — |
| 042 | Pharmaceutical, medical and scientific research; providing scientific research information; research in the field of gene therapy; services for assessing the efficiency of pharmaceutical and medical preparations and substances; clinical trials; pharmaceutical and biopharmaceutical drug development services; research, and development of pharmaceutical preparations for gene therapy; biotechnology research services; research and development of platform technologies for genetic delivery of therapies and pharmaceuticals; research and development regarding the use of screening platforms to discover, research and develop novel capsids for genetic delivery of gene therapies and pharmaceuticals; research and development regarding the identification and targeting of specific cells and tissues for gene therapy delivery; providing medical and scientific research information on the prevention, diagnosis, and treatment of kidney diseases; providing a website featuring medical information and medical research; platform as a service (PaaS) featuring computer software platforms in the field of drug discovery and drug development. | ACTIVE | — |
| 044 | Pharmaceutical and medical services; medical diagnostic and screening services; health care services; advisory services in the fields of medicine and pharmacology; consultancy and information services relating to pharmaceutical and medical preparations and substances; medical diagnosis and treatment of kidney diseases; medical testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of kidney diseases; pharmaceutical and medical information. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Purespring Therapeutics Limited
- Other trademarks owned by Purespring Therapeutics Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named GLOMTHERA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 8, 2026 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jul 23, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 4, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 4, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 14, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 13, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 7, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 15, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 15, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 12, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |